The pharmaceutical company Remedica Limited, in consultation with the Pharmaceutical Services of the Ministry of Health, has announced the voluntary recall of specific batches of the antibiotic medicines Clarem (Clarithromycin) 250mg and 500mg film-coated tablets, as well as Ermyced 250mg/5ml powder for oral suspension (Erythromycin).
The recall concerns the following batches:
Clarem 250mg (Clarithromycin): Batch 108721, expiry 02/2026.
Clarem 500mg (Clarithromycin): Batches 108957 (02/2026), 116948 (11/2026), 119009 (11/2026), 124831 (09/2027).
Ermyced 250mg/5ml (Erythromycin): Batch 126212, expiry 08/2028.
According to Remedica, the decision is precautionary and aligns with similar actions in the European Union. The recall follows the suspension of the Certificate of Suitability of manufacturer SM Biomed by European Regulatory Authorities.
Clarem and Ermyced are prescription-only antibiotics for bacterial infections and short-term use only. The company states that “there is no reason for concern” regarding the products involved. Patients using the affected medicines should consult their doctor or pharmacist for alternative treatment options.
Remedica says it remains committed to protecting patient health and safety. The company does not rule out further measures or announcements if new information emerges.
Also read: Additional 132 vehicles vecalled for defective Takata airbags
For more videos and updates, check out our YouTube channel
